Blood & Plasma Components Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products), By Application (Hematology, Solid Tumor Management, Others), By End User (Hospitals & Clinics, Diagnostic Laboratories, Others), By Region and Competition, 2020-2030F

Market Overview

The Global Blood & Plasma Components Market was valued at USD 45.27 billion in 2024 and is expected to reach USD 66.21 billion by 2030 with a CAGR of 6.54% during the forecast period. The major factors include growing volume of surgeries, surge in the prevalence of trauma and road accidents, and increase in number of people from chronic conditions including cancer are curbing the growth of the market. Blood is life-sustaining fluid that flows throughout the body giving nourishment, electrolytes, hormones, antibodies, and vitamins to body tissues. Plasma is a part of blood which is aqueous in nature, it contains salt and proteins in which platelets, white blood cells and red blood cells are suspended. The other factors supporting the market’s growth are, rising awareness associated with the significance of blood donations, high patient pool, government initiatives, increasing investments for research and development activities, several blood donation campaigns undertaken by various blood organizations, rise in the elderly population base, rise in R&D activities, and technological advancements. Also, the strategic initiatives such as partnerships and product launches undertaken by the market players are augmenting the growth of the market.

Key Market Drivers

Aging Populations and Rising Demand for Transfusion Support

One of the strongest forces driving the blood and plasma components market is the steady aging of populations worldwide. Older adults undergo more surgeries, face higher rates of cancer, and experience chronic conditions that often require transfusion support. Red blood cells are essential for treating anemia and blood loss, platelets are critical for patients undergoing chemotherapy, and plasma is widely used in trauma and surgical settings. As life expectancy increases, these medical needs expand significantly. Government data highlights this shift. For example, the World Health Organization (WHO) projects that by 2050, 1 in 6 people globally will be over the age of 65, compared to 1 in 11 in 2019. In high-income countries such as the United States, Japan, and those across Europe, more than 20% of the population is already above 65 years. Hospital statistics consistently show that most transfusion recipients fall within this age group, reflecting how demographic changes directly impact demand for blood and plasma components.

National blood services in many countries report higher utilization of red blood cells and plasma in surgeries for older adults, such as joint replacements, cardiovascular interventions, and oncology treatments. This predictable increase in demand requires robust collection systems and efficient distribution networks. Governments are responding by investing in donor recruitment programs, upgrading collection technologies, and adopting stricter inventory management protocols.

Expanding Need for Plasma-Derived Therapies and Immunoglobulins

Another major driver comes from the expanding therapeutic use of plasma-derived medicinal products (PDMPs). These include immunoglobulins (IVIG), clotting factors, and albumin, which are vital in treating conditions such as immunodeficiencies, autoimmune diseases, and bleeding disorders. Unlike whole blood transfusions, these products require highly specialized fractionation of large plasma volumes, making plasma a strategic healthcare resource.

Government and public health bodies have highlighted the growing need for immunoglobulin therapies. For instance, in Europe, demand for IVIG has increased by nearly 6–8% annually over the past decade, reflecting its expanding use in neurology and hematology. Similarly, in the United States, the Food and Drug Administration (FDA) recognizes plasma as an essential raw material, noting that the country supplies more than 60% of the world’s source plasma through its extensive donor network.

Download Free Sample Report

Key Market Challenges

Donation Shortfalls and Episodic Supply Instability

One of the biggest challenges facing the blood and plasma components market is the consistent shortage of donations. Despite being a universal medical need, only a small fraction of eligible populations donates regularly. According to the WHO Global Status Report on Blood Safety and Availability, over 118 million blood donations are collected annually worldwide, but nearly 40% of these come from high-income countries, which account for only a fraction of the global population. This imbalance highlights how low- and middle-income countries often struggle to maintain stable supplies. Even in advanced health systems, donation rates fluctuate seasonally. For instance, during holidays or crises such as the COVID-19 pandemic, donor turnout fell sharply, leading to critical shortages in hospitals. The U.S. American Red Cross frequently issues urgent appeals, citing that blood inventories sometimes drop to less than a three-day supply. Such instability forces hospitals to postpone elective surgeries and prioritize only emergency cases.

Recruitment and retention of donors remain long-term concerns. Barriers such as lack of awareness, cultural attitudes, and logistical inconveniences reduce donation participation. Furthermore, with aging populations, donor pools themselves are shrinking, as older individuals often become ineligible due to health conditions.

Safety Concerns, Pathogen Threats, and Rising Testing Costs

Another critical challenge is ensuring the safety of blood and plasma supplies. While transfusions save millions of lives, they also carry the risk of transmitting infectious diseases. Governments require rigorous testing for HIV, hepatitis B and C, syphilis, and other pathogens. However, emerging infectious threats, such as Zika virus, West Nile virus, and COVID-19, have raised new concerns, prompting rapid changes in donor screening and testing protocols.

Implementing advanced screening methods, such as nucleic acid testing (NAT) and pathogen reduction technologies (PRT), significantly improves safety but also increases operational costs. According to the U.S. Centers for Disease Control and Prevention (CDC), ensuring comprehensive testing adds substantial financial and logistical burdens to blood services. Similarly, European health agencies have highlighted the economic strain of adopting pathogen inactivation systems for platelets and plasma, especially given their short shelf lives.

For plasma-derived products, fractionation and viral inactivation steps add another layer of complexity. Regulatory frameworks require strict quality control and traceability, which increase costs for manufacturers and slow down supply. In lower-resource settings, these requirements can become barriers, leading to disparities in access to safe blood components.

Key Market Trends

Consolidation and Investment in Plasma Collection Networks

A notable trend in the market is the consolidation of plasma collection and fractionation activities. Major healthcare and biopharmaceutical companies are investing heavily in establishing new plasma donation centers and upgrading existing infrastructure. The U.S., which already dominates global plasma collection, continues to expand its network, with thousands of donation sites providing the bulk of raw material for plasma-derived therapies.

Governments are also pushing for self-sufficiency. For example, the European Commission has stressed the need to strengthen plasma collection within Europe to reduce dependence on imports, especially from the U.S. Similarly, China has invested in expanding fractionation plants to meet its domestic demand. This consolidation and vertical integration allow larger players to secure supply chains, control costs, and ensure greater resilience against disruptions.

While this trend improves supply security, it also raises questions about equitable access, donor protection, and potential monopolization. Smaller players may find it difficult to compete with large multinational plasma collectors and fractionators. Nonetheless, the drive toward building stronger plasma networks ensures that global demand for immunoglobulins and other PDMPs can be met more consistently in the future.

Digital Transformation and Research into Substitutes

Another trend shaping the market is the adoption of digital technologies and innovation in alternatives to natural blood products. Many national blood services are implementing digital platforms to improve donor engagement, manage appointments, and use predictive analytics for inventory management. This has proven particularly useful for managing platelet supplies, which have very short shelf lives of just five to seven days. By reducing wastage and ensuring better donor-targeting strategies, digitalization is making blood services more efficient.

In parallel, governments and research institutions are funding studies into blood substitutes and engineered solutions. For example, recombinant clotting factors have already replaced plasma-derived options for hemophilia patients in many countries. Research into artificial red blood cells and oxygen carriers is ongoing, with the U.S. Department of Defense funding projects to develop substitutes for battlefield use. While these innovations are not yet widely commercialized, they signal a future where reliance on donor blood may decrease for certain indications.

Segmental Insights

Product Insights

Based on Product, Packed Red Blood Cells (PRBCs) account for the largest market share in the global blood and plasma components industry. This dominance is primarily due to the high demand for red cell transfusions in a wide range of medical conditions such as trauma, surgery, anemia, cancer treatment, and maternal complications. According to the World Health Organization (WHO), more than 118 million blood donations are collected globally every year, and a large proportion is processed into PRBCs for transfusion. Red cell transfusion is often a life-saving intervention and is considered essential in emergency care, surgical procedures, and for managing chronic blood disorders. For instance, in the United States, the American Red Cross reports that nearly 29,000 units of red blood cells are needed daily to meet hospital demand, highlighting the critical role of PRBCs. The longer shelf life of PRBCs compared to platelets, along with advancements in cold storage and preservation technologies, also contribute to their widespread usage. Furthermore, the rising prevalence of blood-related disorders such as sickle cell anemia and thalassemia in regions like Asia-Pacific and Africa has increased reliance on red cell transfusions. 

Download Free Sample Report

Regional Insights

Based on the region, North America currently represents the largest regional market for blood and plasma components, supported by its advanced healthcare infrastructure, extensive donation networks, and high demand for transfusion and plasma-derived therapies. The United States alone accounts for most of the plasma collection worldwide, producing more than 60% of global source plasma, according to government and public health data. This dominance is largely due to the presence of thousands of licensed plasma donation centers across the U.S., coupled with policies that allow compensated plasma donations—an approach not widely practiced in Europe or Asia. The demand side is equally strong. The Centers for Disease Control and Prevention (CDC) reports that around 21 million blood components are transfused each year in the United States, highlighting the sheer scale of usage. A significant portion of these transfusions are for patients undergoing cancer therapies, trauma care, cardiovascular surgeries, and organ transplants—all of which are prevalent in North America due to both high disease burden and a large aging population.

Key Market Players

• CSL Limited
• Grifols S.A.
• ADMA Biologics, Inc.
• Takeda Pharmaceutical Company Limited
• Octapharma AG
• Kedrion S.p.A
• Emergent BioSolutions Inc.
• Bio Products Laboratory Ltd.
• LFB S.A.
• Versiti, Inc.

Report Scope:

In this report, the Global Blood & Plasma Components Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Blood & Plasma Components Market, By Product:

o   Packed Red Blood Cells

o   Platelets Products

o   Frozen Plasma

o   Plasma Derived Products

• Blood & Plasma Components Market, By Application:

o   Hematology

o   Solid Tumor Management

o   Others

• Blood & Plasma Components Market, By End User:

o   Hospitals & Clinics

o   Diagnostic Laboratories

o   Others

• Blood & Plasma Components Market, By Region:

o   North America

§  United States

§  Mexico

§  Canada

o   Europe

§  France

§  Germany

§  United Kingdom

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Japan

§  Australia

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East and Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Blood & Plasma Components Market.

Available Customizations:

Global Blood & Plasma Components Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Blood & Plasma Components Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]